Mazdutide: Uses, Benefits & Research

What is Mazdutide?

Mazdutide (IBI362) is a synthetic peptide developed by Innovent Biologics (China) that acts as a dual GLP-1 and glucagon (GCG) receptor agonist. It became the world’s first approved GCG/GLP-1 dual receptor agonist when China’s National Medical Products Administration (NMPA) granted approval in September 2025 for glycemic control in adults with Type 2 Diabetes.

Administered as a once-weekly subcutaneous injection at doses of 3 mg, 6 mg, or 9 mg, mazdutide represents a new class of metabolic therapeutics that go beyond GLP-1 monotherapy by adding glucagon receptor activation for enhanced energy expenditure and hepatic lipid metabolism.

Mazdutide is not FDA approved and is only legally available in China as of March 2026.

Mechanism of Action

Mazdutide’s dual mechanism targets two complementary metabolic pathways:

GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, delays gastric emptying, and reduces appetite through central satiety signaling. This is the same mechanism used by semaglutide, tirzepatide, and other GLP-1 receptor agonists.

Glucagon receptor activation: Enhances hepatic energy expenditure, promotes lipid oxidation in the liver, and increases thermogenesis. This additional pathway provides metabolic benefits beyond what GLP-1 alone can achieve — validated by the DREAMS-3 trial showing superiority over semaglutide.

The dual mechanism’s clinical advantage was confirmed in head-to-head Phase 3 data: mazdutide produced greater glycemic control and weight loss than semaglutide monotherapy.

Clinical Evidence

Human Studies

Mazdutide has a robust clinical evidence base of approximately 5-10 RCTs:

• Phase 3 GLORY-2 (Obesity, 2025): Randomized, double-blind, placebo-controlled trial in Chinese adults with obesity. The 9 mg dose achieved up to 20.1% body weight reduction, meeting all primary and key secondary endpoints.
• Phase 3 DREAMS-3 (Head-to-Head, 2025): Randomized, open-label, head-to-head comparison against semaglutide in Chinese adults with Type 2 Diabetes. Mazdutide demonstrated superiority in both glycemic control and weight loss — the first Phase 3 trial to show dual agonist superiority over GLP-1 monotherapy.
• Phase 3 T2D Approval Trial: Randomized, double-blind, placebo-controlled trial leading to NMPA approval. Showed significant glucose-lowering efficacy and potential superiority over dulaglutide in weight reduction.
• Phase 2 Obesity (PMID: 38092790): 24-week treatment with mazdutide up to 6 mg was safe and produced clinically meaningful weight reduction.
• Phase 2 T2D (Diabetes Care, 2024): Mazdutide up to 6 mg demonstrated clinically meaningful HbA1c and body weight reductions.

Preclinical

Preclinical studies confirmed dual GLP-1R and GCGR agonist activity, enhanced weight reduction and glycemic control in diabetic/obese animal models, and acceptable safety in toxicology studies.

Drug Interactions & Contraindications

Mazdutide shares class-level drug interaction concerns with other GLP-1 receptor agonists. Insulin and sulfonylureas pose documented additive hypoglycemic risk — dose reduction may be required. Delayed gastric emptying may slow absorption of co-administered oral medications. No specific interaction data exists for non-Chinese populations.

Contraindicated in patients with hypersensitivity to the compound, personal or family history of medullary thyroid carcinoma, and MEN2 syndrome.

Safety & Side Effects

The safety profile is consistent with the GLP-1 receptor agonist class. Common adverse events include nausea, vomiting, diarrhea, decreased appetite, and constipation. No new safety signals were reported in Phase 3 trials. Theoretical concerns based on the dual mechanism include gastroparesis risk, potential hyperglucagonemia, and thyroid C-cell tumor risk (GLP-1 class effect).

All Phase 2/3 data comes from Chinese populations — safety and tolerability in other ethnic groups has not been established.

Honest Bottom Line

Mazdutide is the world’s first approved GLP-1/glucagon dual receptor agonist, with strong Phase 3 data showing up to 20.1% weight loss and head-to-head superiority over semaglutide. The NMPA approval in China validates the dual agonist approach. However, mazdutide is not FDA approved and is only available in China — patients elsewhere cannot legally obtain it. The evidence base is strong for Chinese populations but lacks data in other ethnic groups. No US or EMA trials are publicly announced as of March 2026. Patients globally should continue using approved GLP-1 therapies in their jurisdiction while monitoring mazdutide’s international development.